WELCOME TO #ESHMPN2022

 


9th Translational Research Conference




MYELOPROLIFERATIVE NEOPLASMS


 


May 12-15, 2022




E-Conference - #ESHMPN2022




Chairs: Jean-Jacques Kiladjian (Paris), Ross L. Levine (New York),
Alessandro Vannucchi (Florence)




---

---

Highlights of Day 1

14:00-14:05  Welcome
Jean-Jacques Kiladjian (Paris), Ross L. Levine (New York),Alessandro M. Vannucchi (Florence)

14:05-15:50  Session I: Molecular pathogenesis of MPNs
Chair: Raajit K. Rampal (New York)
Interactive Live Panel Discussion at 15:20

16:00-17:25 Session II: Novel MPN therapeutics
Chair: Radek Skoda (Basel)
Interactive Live Panel Discussion at 16:55

17:35-18:35  Mentored Poster Walk
Leaders: David Kent (York), Sara Meyer (Bern)


Highlights of Day 2

14:10-15:55 Session III: MPN Initiation and clonal evolution
Chair: Simón Méndez-Ferrer (Cambridge)
Interactive Live Panel Discussion at 15:25

16:05-18:05 Session IV: Murine MPN modelsand pathogenesis/therapeutic studies
Chair: Ann Mullally (Boston)
Keynote Lecture at 17:10: New Insights into the roleof JAK2V617F in MPN pathogenesis
Ross L. Levine (New York)
Interactive Live Panel Discussion at 17:45

19:25-20:25  3 Simultaneous Meet the Expert sessions (non-clinical)
PRE-REGISTRATION REQUIRED
- Role of inflammation in MPN
Angela Fleischman (Irvine)
- Cellular and molecular regulators of HSCsin myeloid malignancies
David Kent (York), Sara Meyer (Bern)
- HSC niches in MPN
Simón Méndez-Ferrer (Cambridge)


Highlights of Day 3

14:10-15:55 Session V: Molecular pathogenesis and therapy of MPN progression and leukaemic transformation
Chair: Raajit K. Rampal (New York) Interactive Live Panel Discussion at 15:25

16:05-17:35 Session VI: Recent advances in therapeutics (1)
Chair: Jean-Jacques Kiladjian (Paris)
Keynote Lecture at 16:10: Combination therapiesfor myelofibrosis
Ruben Mesa (San Antonio)
Interactive Live Discussion at 17:05

18:05-19:50 Session VII: Recent advances in therapeutics (2)
Chair: Alessandro M. Vannucchi (Florence)
Interactive Live Panel Discussion at 19:20

 

Highlights of Day 4

 

13:00-14:00  3 Simultaneous Meet the Expert sessions (clinical)
PRE-REGISTRATION REQUIRED
- Novel and Emerging Therapeutic Approaches for MPNs
Raajit K. Rampal (New York), Ross L. Levine (New York)
- How to recognize and manage ruxolitinib treatment failure?
John O. Mascarenhas (New York),Alessandro M. Vannucchi (Florence)
- MPN diagnosis: the place of red cell mass measurement in the molecular era
Stéphane Giraudier (Paris), Jean-Jacques Kiladjian (Paris)

14:10-15:55 Session VIII: Molecular pathogenesis of MPNs
Chair: Angela Fleischman (Irvine)
Interactive Live Panel Discussion at 15:25

16:05-17:50. Session IX: Novel MPN therapeutics
Chair: Stefan N. Constantinescu (Brussels)
Interactive Live Panel Discussion at 17:20

17:05-17:15  Closing remarks
E-Conference chairpersons: Jean-Jacques Kiladjian (Paris),Ross L. Levine (New York), Alessandro M. Vannucchi (Florence)

---

Take a virtual tour of the E-Conference platform
and make yourself at home!

---

About the Conference:

New insights into the molecular pathogenesis, classification, and management of patients with Myeloproliferative Neoplasms (MPN) have arisen at increasing pace during the past years. This International Conference brings together scientists and clinicians to present and discuss new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.

The field of MPN research is rapidly expanding and consequently treatment options are changing. Clinical and laboratory investigators involved in the care of MPN patients or in research on the biology of these diseases will profit from hearing international leaders present the newest biological, clinical and therapeutic developments in the field.

The format of the scientific programme is deliberately designed to be conducive to close scientific interaction between speakers and registered participants from all over the world.

---




CONFERENCE MAIN TOPICS:


• Molecular pathogenesis of MPNs

• Novel MPN therapeutics

• MPN initiation and clonal evolution

• Murine MPN models and pathogenesis/therapeutic studies

• Molecular pathogenesis and therapy of MPN progression and
leukaemic transformation

• Recent advances in therapeutics


 

---

LEARNING OBJECTIVES


Upon completion of this CME activity, participants should be able:


• To understand the newest discoveries on the molecular pathogenesis of MPN
• To appreciate recent changes in treatment recommendations for MPN patients including
the evolving landscape of approved therapies

• To gain insight into ongoing clinical trials investigating novel agents for MPN treatment

• To increase knowledge about cellular and animal models of MPN and their use
for drug screening

THE PROGRAMME WILL INCLUDE:


 Keynote Lectures - Plenary Sessions - Simultaneous Meet the Expert Sessions - Mentored Poster Walks
Short Oral Communications- Ample time for in-depth discussion

CHECK THE SCIENTIFIC PROGRAMME

MORE INFORMATION

---

DO NOT MISS THE OPPORTUNITY!
YOU CAN ALSO REGISTER NOW
FOR THE MEET THE EXPERT SESSIONS

ABOUT THE MEET THE EXPERT SESSIONS

The 9th Translational Research Conference on MYELOPROLIFERATIVE NEOPLASMS Meet the Expert sessions are live, interactive sessions that offer you an opportunity for informal dialogue with world authorities. The number of seats available is strictly limited, first come-first serve*. The sessions will not be recorded.

There will be no formal presentation. The Session Leaders are present to answer your questions and to provide you with expert guidance.  

Registration Fee: 20 euros

*These sessions are open to registered academic biologists and clinicians only.

---




With the support of*:


 










Level 1 E-Conference Partners

*******





Level 2 E-Conference Partners
*******





Supporting E-Conference Partners

*******

* ESH conference programmes are developed in strict scientific independence

with no input from corporate sponsors.